Experimental models for HIV latency and molecular tools for reservoir quantification-an update

Clin Microbiol Rev. 2023 Dec 20;36(4):e0001323. doi: 10.1128/cmr.00013-23. Epub 2023 Nov 15.

Abstract

A major impediment for HIV cure is the ability of the virus to integrate its genome in the form of replication-competent proviral DNA into the cellular genome of the host and remain transcriptionally silent and hidden from the host's immune defense mechanisms in latent reservoir cells. These latent reservoirs are highly heterogeneous, long-lived cells that are capable of reactivating to restore the viremic stage in virally suppressed individuals upon treatment interruption, thus necessitating life-long antiretroviral treatment. Latency reversal has become one of the most explored therapeutic approaches for eliminating HIV reservoirs and effecting HIV cure. Various aspects governing the establishment, maintenance, and reversal of HIV latency continue to be an enigma and warrant further research. Quantifying the size of the latent reservoir pool is also a challenge as these cells are very few in number and cannot be easily differentiated from uninfected cells. This article provides a comprehensive review of the in vitro and in vivo models currently available for studying HIV latency as well as the recently developed molecular tools for detection and quantification of latent viral reservoirs.

Keywords: Human immunodeficiency virus; in vitro and in vivo models; latency; reservoir quantification.

Publication types

  • Review

MeSH terms

  • Anti-Retroviral Agents / therapeutic use
  • CD4-Positive T-Lymphocytes
  • HIV Infections* / drug therapy
  • Humans
  • Models, Theoretical
  • Virus Latency*

Substances

  • Anti-Retroviral Agents